1373313-89-3

Upstream product

• 1373313-77-9 (3aS,4S,6aR)-2,2-dimethyl-6-vinyl-3a,6a-dihydro-4H-cyclopenta[d][1,3]dioxol-4-ol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 67814-68-0 2,3-O-isopropylidene-D-ribofuranose 
• 141436-58-0 (-)-(1R)-1-[(4R,5S)-5-((1S)-1-hydroxyallyl)-2,2-dimethyl[1,3]dioxolan-4-yl]ethane-1,2-diol 

Downstream Products

• 1373313-90-6 [3-(tert-butyldiphenylsilyloxy)-4,5-(O,O-isopropylidenedihydroxy)-1-cyclopentene-1-yl]ethanol 
• 1373313-91-7 2,2-dimethylpropionic acid 2-[(2R,3R,4S)-4-(tert-butyldiphenylsilanyloxy)-2,3-(O-isopropylidenedioxy)cyclopent-1⁽⁵⁾enyl]ethyl ester 

Relevant academic research and scientific papers

Stereoselective synthesis of fluoro-homoneplanocin A as a potential antiviral agent

Fluoro-homoneplanocin A (4) was synthesized from d-ribose, via the enyne ring-closing metathesis of 9, the stereoselective opening of epoxide 23a with fluoride, and a simultaneous oxidation-elimination reaction. The key intermediate 8 is expected to serve

Fluoro-homoneplanocin A and nucleoside derivatives, method for the synthesis thereof, and the pharmaceutical compositions comprising the same as an active component for treatment of cancer

The present invention relates to a fluoro-homoneplanocin A, its nucleoside derivative, and synthetic methods. The novel fluoro-homoneplanocin A and its nucleoside derivative in the present invention have an effect on cancer prevention or treatment, and therefore can be used as anticancer drugs.